Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate...
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™...
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025...
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM,...
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company...
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics...
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated,...
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of...
Enteral ventilation concept from scientist at Cincinnati Children's passes first stage of human testing in Japan CINCINNATI, Oct. 20, 2025...
INDIANAPOLIS, Oct. 20, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform, today announced the 12 companies selected...
HDAI collaborates with Dana-Farber to help clinicians improve goal-concordant care for patients with serious illness BOSTON, Oct. 20, 2025 /PRNewswire/...
New AI-powered EHR will replace multiple information systems and connect care teams across the hospital system to provide high-quality care...
New integrated platform will transform early-stage research, equipping scientists worldwide to uncover disease mechanisms earlier and advance progress toward therapies...
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
NAPLES, FL / ACCESS Newswire / October 20, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell...
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA...
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and...